Background: In the past, interferon use made it challenging to treat hepatitis C virus (HCV) infection in people with chronic renal disease (IFN). Due to decreased renal clearance of IFN, it was linked to IFN-related adverse events with a significant risk. Objective: This study aimed to evaluate the antiviral efficacy, safety, and tolerability of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in chronic kidney disease patients infected with chronic HCV. Patients and Methods: This study was conducted on HCV patients who undergo haemodialysis and patients with normal renal functions who had taken OBV/PTV/r. The study was done at the period from May 2017 to May 2018. The study included 47 patients with chronic HCV infection on regular dialysis (study group) and 50 patients with chronic HCV infection (control group). Results: In our cohort, the mean age of the study group was 43.43 ± 10.56 years while mean age of the control group was 46.80 ± 6.86 years. The majority of the studied groups were males. It was noticed that all enrolled subjects enrolled in the study achieved sustained virological response (SVR) at 12 weeks and 24 weeks. The most frequent adverse effects were fatigue, myalgia and epigastric pain. Conclusion: Paritaprevir/ritonavir and ombitasvir for 12 weeks were considered to be safe and effective in the treatment of chronic HCV infected patients with end stage renal disease.